What is Vabysmo (faricimab) used for?
Vabysmo is an eye medicine used to treat retinal diseases. It contains faricimab, an antibody designed to block pathways involved in abnormal blood vessel growth and leakage in the eye.
How is Vabysmo given?
Vabysmo is administered as an intravitreal injection, meaning it is injected into the vitreous (inside) the eye by an ophthalmologist.
What conditions can Vabysmo treat?
Vabysmo is used for major forms of retinal disease that involve abnormal vascular activity, including:
- Age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy conditions involving macular edema (as indicated in prescribing guidance)
How often are injections?
Dosing schedules depend on the individual disease and response to treatment. Many faricimab regimens are structured around regular follow-up visits and may extend dosing intervals in some patients once disease control is achieved (based on the prescriber’s protocol and the product’s labeled schedule).
What side effects do patients ask about?
Common concerns for intravitreal injections generally include:
- Eye pain or discomfort
- Temporary changes in vision after the injection
- Risk of inflammation inside the eye
- Risk of infection (endophthalmitis) and other serious injection-related complications, though these are uncommon
Is Vabysmo still protected by patents and exclusivity?
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines. You can check Vabysmo’s patent/exclusivity status there to see when key protections may expire: DrugPatentWatch: Vabysmo
What might replace Vabysmo if it’s unavailable or you’re switching?
Switching can happen for clinical reasons (response, tolerability, treatment interval) or practical reasons (availability). Options typically include other intravitreal anti-VEGF therapies used for wet AMD and diabetic macular edema, though the best choice depends on your diagnosis and treatment history.
---
Sources:
1. https://drugpatentwatch.com/